Latest news with #Femasys
Yahoo
6 days ago
- Business
- Yahoo
Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the 'Company' or 'Femasys'), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated an interest to purchase shares of common stock in a concurrent private placement. All of the securities in the public offering and private placement are being offered by Femasys. The public offering and private placement are subject to market conditions, and there can be no assurance as to whether or when the public offering and private placement may be completed, or as to the actual size or terms of the public offering and private placement. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering. Jones is acting as sole book-running manager for the public offering and placement agent for the private placement. Femasys intends to use the net proceeds from the public offering and private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. The securities offered in the public offering are being offered by the Company pursuant to a Registration Statement on Form S-3 (File No. 333-266001) previously filed with the U.S. Securities and Exchange Commission (the 'SEC') and declared effective by the SEC on July 12, 2022. A preliminary prospectus supplement and the accompanying prospectus relating to the public offering will be filed with the SEC and will be available on the SEC's website at When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained from JonesTrading Institutional Services LLC, Attention: Equity Capital Markets, 325 Hudson Street, 6th Floor New York, New York 10013; email: ecm@ The concurrent private placement of the securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Securities Act') and/or Regulation D thereunder. Accordingly, the securities issued in the concurrent private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. This press release is neither an offer to sell, nor a solicitation of an offer to buy, any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale is unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction. About FemasysFemasys Inc. (NASDAQ: FEMY) is a biomedical company aiming to meet women's needs worldwide by developing a suite of products and product candidates that include minimally invasive, in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company's products currently marketed in the United States, include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®, an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. Forward-Looking Statements This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'pending,' 'intend,' 'believe,' 'suggests,' 'potential,' 'hope,' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect, and include, among others, statements regarding the completion of the public offering and the private placement, the satisfaction of customary closing conditions related to the public offering and the private placement and the anticipated use of proceeds therefrom. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: market and other conditions, our ability to develop and advance our FemBloc product candidates and programs into, and successfully initiate, enroll and complete, the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our FemBloc product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof and ability to raise sufficient capital for such model and plans; and those other risks and uncertainties described in the section titled 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Contacts: Investors: IR@ Media Contact: Media@ in to access your portfolio
Yahoo
21-03-2025
- Business
- Yahoo
Femasys price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm's price target on Femasys (FEMY) to $15 from $12 and keeps a Buy rating on the shares after the company announced that it has established a partnership with CNY Fertility, a national provider of fertility services. The firm has updated its model to include outside of the U.S. sales for FemBloc as the company recently announced EU approval of the FemBloc delivery system and also announced two distributor partnerships in Spain, the analyst tells investors, noting that the firm is now modeling global peak annual sales for FemBloc of $1B, though assuming odds of success of 25%, which it calls 'conservative.' Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor analyses. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on FEMY: Questions or Comments about the article? Write to editor@ Femasys enters partnership with CNY Fertility Femasys's Strategic Expansion and Promising Clinical Results Justify Buy Rating Femasys secures partnerships for commercialization of FemBloc in Spain Femasys Achieves CE Mark for FemBloc, Paving the Way for European Market Entry and Justifying Buy Rating Femasys announces FemBloc delivery system approval in Europe
Yahoo
19-03-2025
- Business
- Yahoo
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces a partnership with CNY Fertility, a national provider of fertility services across the U.S. CNY Fertility will provide the Company's FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of 11 locations. 'We are thrilled to partner with CNY Fertility, a prominent infertility group, to continue to expand access of our FemaSeed infertility treatment to those seeking a first-line fertility solution,' said Femasys CEO Kathy Lee-Sepsick. 'By providing FemaSeed to CNY Fertility, we are supporting their commitment to delivering exceptional care and helping patients navigate their fertility journey with confidence.' Dr. Robert Kiltz, Founder and Director of CNY Fertility stated, 'Our mission at CNY Fertility is to offer comprehensive, affordable, high-quality fertility solutions for our patients. We believe FemaSeed is an innovative technology that expands options for our patients seeking the latest advancements to grow their family.' About FemaSeed FemaSeed® is an innovative advancement in artificial insemination, designed to enhance fertilization by precisely delivering sperm into the fallopian tube, the natural site of conception. It offers a safe, accessible and cost-effective first-line therapeutic option for infertile women, men and couples seeking pregnancy through insemination. FemaSeed offers a revolutionary alternative to IUI, enabling healthcare professionals to expand their practice services with a more effective approach as demonstrated in the pivotal trial (NCT0468847) for low male sperm count.1 It serves as an affordable, less burdensome and lower-risk first step before IVF. Learn more at About Femasys Femasys is a leading biomedical innovator focused on addressing critical unmet needs in women's health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company, a U.S. manufacturer, has received regulatory approvals for its product portfolio worldwide, and they are currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment, is FDA-cleared and approved in Europe, UK, Canada and Israel. Clinical trial data, published in peer-reviewed journal, demonstrate safety, effectiveness, and high satisfaction from patients and practitioners.1 FemVue®, a companion diagnostic for fallopian tube assessment, is FDA-cleared and approved in Europe, UK, Canada, Japan and Israel. FemCerv®, a tissue sampler for cervical cancer diagnosis, is FDA-cleared and approved in Europe, UK, Canada and Israel. FemBloc® permanent birth control, is the first and only non-surgical, in-office approach offering significant benefits over the costly, inconvenient, risk-laden surgical alternative. The revolutionary FemBloc delivery system is approved in Europe and the proprietary blended polymer has been recommended for approval, which is expected mid-year 2025. For U.S. FDA approval, the FINALE pivotal clinical trial (NCT05977751) is currently enrolling participants. Peer-reviewed publication of positive data from its initial clinical trials of FemBloc have demonstrated compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners.2 FemCath® and FemChec®, diagnostic products for FemBloc's ultrasound-based confirmation test, are FDA-cleared and approved in Europe and Canada. Learn more at or follow us on X, Facebook and LinkedIn. About CNY FertilityCNY Fertility is a leading fertility clinic known for its affordable and accessible fertility treatments. With a commitment to excellence in care and a comprehensive suite of services, CNY Fertility helps individuals and couples achieve their dreams of parenthood. Unique in its affordability, inclusiveness, accessibility, geographic reach, professional expertise, and personal service, CNY Fertility has helped create more than 30,000 lives since its opening in 1997 and is expanding its capability to give this gift to many more people. Learn more at References 1 Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. 2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. Forward-Looking Statements This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'pending,' 'intend,' 'believe,' 'suggests,' 'potential,' 'hope,' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable Investors: IR@ Media Contact: Media@
Associated Press
19-03-2025
- Business
- Associated Press
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
ATLANTA, March 19, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces a partnership with CNY Fertility, a national provider of fertility services across the U.S. CNY Fertility will provide the Company's FemaSeed intratubal insemination product as an infertility treatment option to patients throughout its network of 11 locations. 'We are thrilled to partner with CNY Fertility, a prominent infertility group, to continue to expand access of our FemaSeed infertility treatment to those seeking a first-line fertility solution,' said Femasys CEO Kathy Lee-Sepsick. 'By providing FemaSeed to CNY Fertility, we are supporting their commitment to delivering exceptional care and helping patients navigate their fertility journey with confidence.' Dr. Robert Kiltz, Founder and Director of CNY Fertility stated, 'Our mission at CNY Fertility is to offer comprehensive, affordable, high-quality fertility solutions for our patients. We believe FemaSeed is an innovative technology that expands options for our patients seeking the latest advancements to grow their family.' About FemaSeed FemaSeed® is an innovative advancement in artificial insemination, designed to enhance fertilization by precisely delivering sperm into the fallopian tube, the natural site of conception. It offers a safe, accessible and cost-effective first-line therapeutic option for infertile women, men and couples seeking pregnancy through insemination. FemaSeed offers a revolutionary alternative to IUI, enabling healthcare professionals to expand their practice services with a more effective approach as demonstrated in the pivotal trial (NCT0468847) for low male sperm count.1 It serves as an affordable, less burdensome and lower-risk first step before IVF. Learn more at About Femasys Femasys is a leading biomedical innovator focused on addressing critical unmet needs in women's health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. The Company, a U.S. manufacturer, has received regulatory approvals for its product portfolio worldwide, and they are currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment, is FDA-cleared and approved in Europe, UK, Canada and Israel. Clinical trial data, published in peer-reviewed journal, demonstrate safety, effectiveness, and high satisfaction from patients and practitioners.1 FemVue®, a companion diagnostic for fallopian tube assessment, is FDA-cleared and approved in Europe, UK, Canada, Japan and Israel. FemCerv®, a tissue sampler for cervical cancer diagnosis, is FDA-cleared and approved in Europe, UK, Canada and Israel. FemBloc® permanent birth control, is the first and only non-surgical, in-office approach offering significant benefits over the costly, inconvenient, risk-laden surgical alternative. The revolutionary FemBloc delivery system is approved in Europe and the proprietary blended polymer has been recommended for approval, which is expected mid-year 2025. For U.S. FDA approval, the FINALE pivotal clinical trial (NCT05977751) is currently enrolling participants. Peer-reviewed publication of positive data from its initial clinical trials of FemBloc have demonstrated compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners.2 FemCath® and FemChec®, diagnostic products for FemBloc's ultrasound-based confirmation test, are FDA-cleared and approved in Europe and Canada. Learn more at or follow us on X, Facebook and LinkedIn. About CNY Fertility CNY Fertility is a leading fertility clinic known for its affordable and accessible fertility treatments. With a commitment to excellence in care and a comprehensive suite of services, CNY Fertility helps individuals and couples achieve their dreams of parenthood. Unique in its affordability, inclusiveness, accessibility, geographic reach, professional expertise, and personal service, CNY Fertility has helped create more than 30,000 lives since its opening in 1997 and is expanding its capability to give this gift to many more people. Learn more at References 1 Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. 2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. Forward-Looking Statements This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'pending,' 'intend,' 'believe,' 'suggests,' 'potential,' 'hope,' or 'continue' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled 'Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law. Media Contact:
Yahoo
05-02-2025
- Business
- Yahoo
Femasys gains approvals for infertility and diagnostic products in Israel
Femasys has gained approval for its FemaSeed Intratubal Insemination product and two diagnostic devices from the Ministry of Health's (AMAR) Israeli medical device division. The diagnostic devices, FemCerv and FemVue, are designed to identify cervical cancer and tubal assessment, respectively. Intended to improve fertilisation by delivering sperm directly into the fallopian tube, FemaSeed claims to provide a safe and cost-effective alternative for women, men, and couples struggling with infertility who are ready to conceive through the insemination process. A pivotal trial demonstrated the 'effectiveness' of FemaSeed, particularly for cases of low male sperm count, offering a lower-risk alternative before considering in vitro fertilisation (IVF). FemCerv, the first Food and Drug Administration (FDA)-cleared product specifically tailored for collecting a comprehensive and uncontaminated sample, facilitates a pain-free office procedure for cervical cancer identification. It has also gained approvals in Israel, Canada, and Europe. FemVue, another diagnostic device for assessing fallopian tubes via ultrasound, has been cleared by the US regulator and approved in Canada, Israel, Europe and Japan. Headquartered in Atlanta, Femasys develops and commercialises minimally invasive women's health solutions. Companion diagnostic products FemCath and FemChec, used for FemBloc's ultrasound-based confirmation test, have also been cleared by the FDA and gained approval in Canada and Europe. Femasys CEO Kathy Lee-Sepsick said: 'We remain committed to our mission of delivering critically important technological advancements to women globally, with Israel now added to our expanding reach. 'FemaSeed, along with our entire suite of products, has been developed to provide women with better, lower-cost, and more accessible options. We remain focused on commercial execution in the US and select other countries as we continue to expand the availability of our much-needed product solutions.' In August 2024, the company secured CE mark certification and Health Canada approval for FemVue MINI, a compact solution for assessing fallopian tubes. "Femasys gains approvals for infertility and diagnostic products in Israel" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
